Here are some interesting bits from this last call. The focus on busiess development even after their latest deal was interesting.
Business Development (BD) was mentioned several times. "We're excited to use that (balance sheet) wisely in the next year or so". What was mentioned is that they have experience commercialising rare disease assets. It is note worth that Catherine mentioned any rare disease, potentially not just neurological. "We continue to look at opportunities with existing molecules and business development" ... "in the neurological space, also more broadly in rare diseases"
Catherine Is mentioned growth in Daybue for USA several times. She mentioned she in reference to why she wanted to join Acadia and her impact. "Unlock some hidden potential to grow both our products beyond current exceptions" and also referred to other facts we're already aware of in terms of 70% of patients are yet to try Daybue and the real world experience is helping to recruit new patients.
Globalisation of both products was mentioned but plenty of time was spent speaking about Europe and how they have hired resources and they are confident of the demand after speaking to key opinion leaders, advocacy groups in Europe. Japan will take more time, so focus is on Europe.
Slight increase of diagnosis rates in Rett after Daybue launch. Longest child has been on Daybue 4 years. This particular child has had incremental improvements over this entire period which is great but a larger observation study is occuring in the background to confirm this over a larger dataset.
Guidance - Acadia will guide in Q1 we see growth in both of our products
NEU Price at posting:
$12.82 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)